Earnings ·
Oculis Holding AG reported unaudited financial results for the six months ended June 30, 2026
OCSAWOculis Holding AG
Oculis Holding AG reported unaudited financial results for the six months ended June 30, 2026. The company incurred a net loss of CHF 38.8 million ($49.3 million), compared to CHF 58.6 million in the prior year period. Operating expenses totaled CHF 45.8 million, with research and development costs at CHF 29.3 million and general and administrative expenses at CHF 16.5 million. The improved loss performance was primarily driven by a CHF 4.1 million fair value gain on warrant liabilities and favorable foreign currency exchange gains of CHF 1.8 million. Cash, cash equivalents, and short-term investments stood at CHF 228.3 million ($282.3 million) as of June 30, 2026, providing a runway into the second half of 2029. The company continues to advance its neuro-ophthalmology pipeline, including the PIONEER program for Privosegtor and the PREDICT-1 trial for Licaminlimab.